Skip to main content

Unfortunately we don't fully support your browser. If you have the option to, please upgrade to a newer version or use Mozilla Firefox, Microsoft Edge, Google Chrome, or Safari 14 or newer. If you are unable to, and need support, please send us your feedback.

Publish with us

Sponsors & Exhibitors

Commercial opportunities

Choose from a variety of sponsorship and commercial options to raise your profile and position your company as a thought leader in the community.

Download sales packopens in new tab/window

Reasons why being a sponsor is a brilliant marketing strategy

  • Highly targeted marketing – reach your community

  • Brand awareness & recognition – logo and advertisement placement

  • Access to knowledge – find out about new research being undertaken

  • Engage with your audience online

  • Media exposure - benefit from being promoted throughout Elsevier’s marketing process

  • Enhance credibility – highlight your company’s expertise to a captive audience

  • Generate new sales & form new partnerships – with registrants, vendors and speakers

  • Leveraged lead generation - the chance to be recommended to attendees’ connections

To discuss your requirements or to book sponsorship or exhibit space please contact:

Chloe Partridge Conference Sponsorship & Classified Advertising Sales Executive Tel: +44 (0) 1865 843 346 Email: [email protected]opens in new tab/window

Please do not email credit card information under any circumstances



Ovagen is a biotechnology company that has developed a proprietary process of producing the world’s first Germ-Free chicken eggs for use in vaccine manufacture, research & development, and other biopharmaceutical applications. Germ-free eggs transform vaccine production by:

  • Eliminating bacterial contamination and reducing antimicrobial resistance, a holy grail for vaccines

  • Increasing the yield of vaccines per egg

  • Increasing quality, security, and sustainability

  • Reducing carbon footprint, and

  • Allowing more efficient and cost-effective production of vaccines therefore improving access by poorer nations. in new tab/window